Phase II Study of 5-FU, Oxaliplatin Plus Dasatinib in Metastatic Pancreatic Adenocarcinoma
Status:
Completed
Trial end date:
2020-07-01
Target enrollment:
Participant gender:
Summary
The purpose of this research study is to determine if the study drug, dasatinib, given in
combination with 5-Fluorouracil, leucovorin and oxaliplatin (FOLFOX) will work against
metastatic pancreatic cancer.
Dasatinib is a Food and Drug Administration (FDA) approved drug for treating chronic
myelogenous leukemia and acute lymphoblastic leukemia, however it is not currently approved
for use in the treatment of pancreatic cancer.